- Home
- LCFY vs ICCM Comparison
LCFY vs ICCM Comparison
Compare LCFY & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LCFY | ICCM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Australia | Israel |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 8.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LCFY | ICCM |
|---|---|---|
| Price | $2.45 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 7.3K | ★ 94.1K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.51 |
| Revenue Next Year | N/A | $75.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $0.13 |
| 52 Week High | $7.75 | $9.54 |
Technical Indicators
Market Signals| Indicator | LCFY | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 36.84 |
| Support Level | $2.10 | $2.12 |
| Resistance Level | $2.81 | $3.59 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.66 | 11.28 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.